Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Carbogen Amcis Expands High Potency Capabilities | Contract Pharma

What are you searching for?

Sign in
Breaking News

Carbogen Amcis Expands High Potency Capabilities

Adds chromatography suite Bubendorf and a Kilo-lab in Bavla

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Carbogen Amcis AG has expanded its high potency capabilities with a dedicated chromatography suite for Category 3 and 4 compounds at its niche-scale commercial facility for APIs in Bubendorf, Switzerland, and a new 110-m2 Class 100,000 High Potency Kilo-lab at its large-scale commercial facility in Bavla, India.
 
The Bubendorf 55-m2 grade D area features three walk-in barrier hoods for safe handling of highly potent material and a 15 cm ID high performance liquid chromatography (HPLC) column for the purification of highly potent APIs in the range of 50 – 500 g/day. The kilo-lab in Bavla features multiple glass-lined and stainless steel reactors and agitated nutsche filter driers (ANFDs) equipped with charging/discharging isolators. Also, a negative pressure cascade and the HEPA filters allow the safe production of highly potent APIs at exposure limit values between 1 μg/m³ and 50 ng/m³ at eight-hour time weighted average.
 
“The expansions in India and Switzerland continue Carbogen Amcis’ investment in building out a global, high potency platform to meet the growing demand for high potency APIs for oncology applications. This move, along with parallel investments in the ADC arena in France and Switzerland, is a reflection of Carbogen Amcis’ continued commitment to providing a broad range of personalized, expert services, capabilities and geographic choices to our clients to help them develop the next-generation cancer treatments,” said Mark C. Griffiths, chief executive officer, Carbogen Amcis and the Dishman Group.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics